Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 9/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 5/20 | 0.36 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13493005 | 0.91 | TACR3 (0.40) | TACR3PANK3MC4R | |
| SCHEMBL1947861 | 0.91 | TACR3 (0.40) | TACR3PANK3MC4R | |
| SCHEMBL15016247 | 0.91 | TACR3 (0.39) | TACR3PANK3EIF4A3MDM2MC4R | |
| SCHEMBL1945984 | 0.84 | MDM2 (0.34) | TACR3EIF4A3MDM2 | |
| SCHEMBL12536495 | 0.83 | TACR3 (0.42) | TACR3PANK3EIF4A3MC4R | |
| SCHEMBL15016249 | 0.82 | TACR3 (0.40) | TACR3PANK3EIF4A3MDM2MC4R | |
| SCHEMBL12536372 | 0.82 | TACR3 (0.42) | TACR3PANK3MC4R | |
| SCHEMBL12536654 | 0.81 | TACR3 (0.41) | TACR3PANK3MC4R | |
| SCHEMBL12536905 | 0.81 | TACR3 (0.39) | TACR3PANK3 | |
| SCHEMBL12537017 | 0.79 | TACR3 (0.41) | TACR3PANK3MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592403-B2 | Diazepine and diazocane compounds as MC4 agonists | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | claimed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | claimed |
| US-8592403-B2 | Diazepine and diazocane compounds as MC4 agonists | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2326638-B9 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LTD (GB) | 2013-11-13 | — | — | EP | disclosed |
| EP-2326638-B1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | PFIZER LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | TACR3 194/4885PANK3 3957/4885EIF4A3 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.